Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.11%. A quarter ago, it was expected that this company would post a loss of $0.40 per share when it actually produced a loss of $0.34, delivering a surprise of 15%.Over the last four quarters, the company has surpassed consens ...

Seer (SEER) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SEER First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please pr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) (S ...

First Quarter 2025 Financial Results Revenue was $4.2 million for the first quarter of 2025, a 37% increase from $3.1 million for the corresponding prior year period, primarily due to higher product sales and service revenue in the quarter. Product revenue for the first quarter of 2025 was $2.9 million, including $5 thousand of related party revenue, and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $1.2 million for the first quarter of 2025, including $47 thousand o ...

Revenue grew 37%, driven by increased product sales and service revenueREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery ...

REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An ar ...

Seer, Inc. (SEER) has been beaten down lately with too much selling pressure. While the stock has lost 16.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator tha ...

A downtrend has been apparent in Seer, Inc. (SEER) lately with too much selling pressure. The stock has declined 16.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spot ...

Core Viewpoint - Seer, Inc. (SEER) has experienced a significant downtrend, with a 10.5% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - The stock is currently oversold, indicated by an RSI reading of 26.76, which is below the typical threshold of 30 [5]. - The heavy selling pressure on SEER shares appears to be exhausting, indicating a possible reversal in the stock's trend [5]. Group 2: Earnings Estimates and Analyst Consensus - Over the last 30 days, the consensus EPS estimate for SEER has increased by 10.8%, reflecting strong agreement among analysts regarding improved earnings [6]. - SEER holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7].

Financial Performance - The company incurred net losses of $86.6 million and $86.3 million in 2024 and 2023, respectively, with an accumulated deficit of $392.4 million as of December 31, 2024[203]. - The company has a limited operating history, making it difficult to predict future performance and viability[204]. - Fluctuations in operating results may occur due to factors such as demand for products, sales cycle length, and competition[208]. - The company may need to raise additional capital to fund commercialization plans for the Proteograph Product Suite[281]. - The company believes its current cash, cash equivalents, and investments will be sufficient for at least twelve months from the date of the Annual Report[281]. - The company may consider raising additional capital for expanding sales and marketing efforts for the Proteograph Product Suite[282]. Product Development and Commercialization - The company is in the early stages of commercialization of the Proteograph Product Suite, which may not be successfully executed as planned due to various challenges[216]. - The company expects to continue to devote substantially all resources towards the development and commercialization of the Proteograph Product Suite and related products and services[203]. - The success of the Proteograph Product Suite depends on broad scientific and market acceptance, which may take longer than anticipated[218]. - The commercialization success of the Proteograph Product Suite is contingent upon establishing capabilities and value propositions with key opinion leaders and customers[218]. - Future revenue growth will depend on the successful enhancement and introduction of new products and services related to the Proteograph[228]. - The company anticipates that the Proteograph Product Suite will increase study sizes for customers, which is crucial for consumable sales and associated revenue[242]. Market Risks and Competition - The market for the Proteograph Product Suite may be smaller than estimated, and new market opportunities may not develop as quickly as expected, limiting sales potential[214]. - The company faces significant competition in the life sciences technology market from companies like Agilent Technologies and Thermo Fisher Scientific[277]. - Economic downturns and reduced research funding could adversely affect demand for the Proteograph Product Suite and overall business operations[232][245]. - The company faces risks in successfully commercializing the Proteograph Product Suite due to limited experience in sales and marketing, which may impact market acceptance[225]. Operational Challenges - The company faces risks related to recruiting and retaining qualified employees, which may impact operations[206]. - The ability to maintain effective internal controls is crucial for accurate financial reporting, affecting investor confidence[206]. - The company must enhance operational functions, including customer support and quality assurance, to support the commercialization of the Proteograph Product Suite[258]. - The company relies on external suppliers and service providers, which adds complexity and risk to the management of development projects[229]. - The company relies on a single contract manufacturer, Hamilton Company, for the production of its instruments, which poses risks if Hamilton fails to meet demand or quality standards[250]. - There is a risk of supply chain disruptions due to reliance on limited suppliers for critical components, which could hinder production capabilities[253]. Regulatory and Compliance Issues - The company faces potential risks related to compliance with international regulations, including the European Union's GDPR, which could increase operational costs and affect revenue[270]. - The company’s products are currently labeled as research use only (RUO) and are not intended for diagnostic procedures, which may require FDA approval if marketed as medical devices[299]. - The FDA's new Quality Management System Regulation (QMSR) will be enforced starting February 2, 2026, replacing the previous Quality System Regulations (QSR)[300]. - Regulatory compliance costs may increase due to new FDA regulations and potential litigation regarding the regulation of laboratory developed tests (LDTs)[308]. - The company faces risks related to compliance with foreign regulatory requirements, which can vary significantly and impact the commercialization of products outside the U.S.[304]. Intellectual Property Risks - The company relies on patent protection for its products, and failure to maintain adequate intellectual property protection could impair its competitive position[312]. - The patent application process is costly and time-consuming, and there is uncertainty regarding the issuance and enforceability of patents[316]. - Changes in patent laws or interpretations may diminish the value of the company's intellectual property, leading to increased competition[317]. - The company may face claims regarding the wrongful use or disclosure of confidential information, which could lead to litigation and increased competition[354]. - The company relies on licenses from third parties, including BWH, for critical technologies, and losing these licenses could significantly harm its ability to develop and commercialize products[358]. Stock and Market Considerations - The company has a share repurchase program authorized for up to $25.0 million of its Class A common stock[388]. - The market price of the company's Class A common stock has been volatile, influenced by factors such as product commercialization and operating results[378]. - The company may not successfully maintain compliance with Nasdaq listing requirements, which could impair liquidity and market price[377]. - The company does not anticipate paying any dividends in the foreseeable future, focusing instead on retaining earnings for operations and R&D[393].